Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

7 months ago 144

The Eli Lilly and Novo Nordisk logos.

Mike Blake | Tom Little | Reuters

It's a tale of two drugmakers in the red-hot obesity drug market.

Both Read Entire Article